Anixa Biosciences (ANIX) Times Interest Earned (2012 - 2026)
Anixa Biosciences' (ANIX) quarterly Times Interest Earned came in at -$1.8 in Q2 2026, up 58.42% YoY from -$1.14 in Q2 2025, and down 462544.1% on a QoQ basis from -$0.0 in Q4 2025.
Anixa Biosciences (ANIX) Times Interest Earned (2012 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 15 years of Times Interest Earned data on file, last reported at -$1.8 in Q2 2026.
- Quarterly Times Interest Earned rose 58.42% year-over-year to -$1.8 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$7.47 (up 60.66% YoY) and the FY2025 annual result came in at -$0.0, up 76.87% from the prior year.
- Times Interest Earned slipped to -$1.8 in Q2 2026, from -$0.0 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.0 in Q4 2023 to a low of -$5.96 in Q2 2024.
- A 5-year average of -$1.82 and a median of -$1.23 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned soared 100.0% — and 2024, when it sank 94643.58%.
- Tracing ANIX's Times Interest Earned over 5 years: stood at -$0.0 in 2022, then rose by 27.47% to -$0.0 in 2023, then slumped by 94643.58% to -$0.08 in 2024, then jumped by 99.53% to -$0.0 in 2025, then tumbled by 462544.1% to -$1.8 in 2026.
- The last three Times Interest Earned figures came in at -$1.8 (Q2 2026), -$0.0 (Q4 2025), and -$1.43 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -1.80 |
| Oct 31, 2025 | 0.00 |
| Jul 31, 2025 | -1.43 |
| Apr 30, 2025 | -4.34 |
| Jan 31, 2025 | -3.10 |
| Oct 31, 2024 | -0.08 |
| Jul 31, 2024 | -2.37 |
| Apr 30, 2024 | -5.96 |
| Jan 31, 2024 | -0.39 |
| Oct 31, 2023 | 0.00 |
| Jul 31, 2023 | -1.23 |
| Apr 30, 2023 | -0.55 |
| Jan 31, 2023 | -0.37 |
| Oct 31, 2022 | 0.00 |
| Jul 31, 2022 | -0.91 |
| Apr 30, 2022 | -2.62 |
| Jan 31, 2022 | -5.74 |
| Oct 31, 2021 | -12,544.62 |
| Jul 31, 2021 | -0.85 |
| Apr 30, 2021 | -0.35 |